Availability of Medication for Opioid Use Disorder Among Accountable Care Organizations: Evidence From a National Survey.
Psychiatr Serv
; 75(2): 182-185, 2024 Feb 01.
Article
in En
| MEDLINE
| ID: mdl-37614155
ABSTRACT
OBJECTIVE:
This report aimed to assess how accountable care organizations (ACOs) addressed ongoing opioid use disorder treatment needs over time.METHODS:
Responses from the 2018 (N=308 organizations) and 2022 (N=276) National Survey of Accountable Care Organizations (response rate=55% in both years) were used to examine changes in availability of medication for opioid use disorder (MOUD) among ACOs with Medicare and Medicaid contracts.RESULTS:
The percentage of respondents offering at least one MOUD grew from 39% in 2018 to 52% in 2022 (p<0.01). MOUDs were more likely to be available in 2022 among ACOs with (vs. without) in-network substance use treatment facilities (80% vs. 33%, p<0.001). The percentage of 2022 respondents who reported offering MOUD was similar in states with high versus low opioid overdose mortality rates.CONCLUSIONS:
Despite growing availability of MOUD among ACOs, nearly half reported not offering any MOUD in 2022, and the availability of MOUD did not increase with treatment need.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Buprenorphine
/
Accountable Care Organizations
/
Opioid-Related Disorders
Limits:
Aged
/
Humans
Country/Region as subject:
America do norte
Language:
En
Journal:
Psychiatr Serv
Journal subject:
PSIQUIATRIA
Year:
2024
Document type:
Article